Bristol-Myers Squibb

BMY

Market cap $117B

Deutsche Bank has raised its price target on Bloomsbury Publishing PLC (LSE:BMY) to 760p from 700p, reiterating a buy rating on the FTSE-listed publisher after full-year results came in broadly in line with expectations. Full-year results to February were consistent with the trading update issued in March, with adjusted fully diluted earnings per share coming in slightly ahead of forecasts due to a better-than-expected tax charge.

Bristol Myers Squibb said on Friday that its experimental oral drug mezigdomide delayed disease progression in a late-stage trial of multiple myeloma patients whose illness had relapsed ​or not responded to other treatments.

Bristol Myers Squibb said Friday its drug, mezigdomide, lowered the risk of progression or death for multiple myeloma patients by over half.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in.

Bristol-Myers Squibb Company sees its business tracking toward the upper end of full-year 2026 revenue and EPS guidance ranges. In my view, this primarily reflects strong demand for Breyanzi, Camzyos, and Reblozyl. Sales of this "trio" were $1.28 billion in Q1, up 42.2% year-over-year.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Bristol Myers Squibb faces a daunting patent cliff. The company has a promising growth portfolio, but it may not be able to fully offset losses from older drugs.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS to Unveil New Data at ASCO 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline.

Bristol Myers Squibb said on Wednesday it is partnering with Anthropic to make ​its Claude AI model available to ‌over 30,000 employees in an effort to accelerate the discovery, development and delivery of new medicines.